S. Gibbs

发表

Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial

D. Dearnaley, C. Parker, M. Mason, 2022, The Lancet. Oncology.

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

R. Laing, M. Parmar, M. Sydes, 2016, The Lancet.

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

Matthew R. Sydes, Duncan B. McLaren, Eleftherios Sideris, 2018, European urology oncology.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array

J. R. Wilson, David M. Holden, P. W. Foster, 2016, British Journal of Cancer.

Transdermal Oestradiol in the Management of Castration-resistant and Corticosteroid-resistant Prostate Cancer — a Dose Escalation Study

J. Shamash, S. Gibbs, S. Mcfaul, 2013 .

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Warren C. Grant, M. Parmar, M. Sydes, 2021, The Lancet.

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

M. Parmar, M. Sydes, D. Dearnaley, 2019 .

Chronic urticaria responding to subcutaneous heparin sodium

S. Gibbs, S. L. Chua, 2005, The British journal of dermatology.

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial

M. Parmar, M. Sydes, F. Saad, 2020, The Lancet.

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

M. Sydes, D. Dearnaley, C. Parker, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

M. Parmar, M. Sydes, D. Dearnaley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer

R. Huddart, V. Khoo, J. Staffurth, 2020, International journal of radiation oncology, biology, physics.

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

D. Amadori, S. Fosså, A. Haese*, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

D. Amadori, S. Fosså, C. Parker, 2011 .

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.

M. Parmar, M. Sydes, D. Dearnaley, 2023, The Lancet. Oncology.

in and metastatic sensitive : long-term results

D. Dearnaley, S. Gibbs, A. Zarkar, 2019 .